For the first time, the U.S. government has successfully negotiated lower prices for 15 high-cost Medicare drugs, creating a powerful precedent that could reshape the entire healthcare industry's economics.
The new pricing structure is projected to save Medicare billions annually starting in 2027, with companies positioned in the cost-efficiency chain poised to capture significant value from these systemic savings.
These carefully selected companies operate at the centre of healthcare cost management, from pharmacy benefit negotiation to patient care coordination, positioning them to benefit as efficiency becomes the industry's primary focus.
This basket's total market capitalisation is $771.48B. It is heavily anchored by a few very large-cap constituents, giving it a predominantly large-cap profile.
UNH: $295.56B
CVS: $99.61B
CI: $74.31B
The U.S. government's successful negotiation of lower Medicare drug prices under the Inflation Reduction Act represents a fundamental shift in healthcare economics. As pricing power moves away from pharmaceutical manufacturers, companies that drive cost efficiency and manage care are positioned to capture enhanced profitability from this regulatory transformation.
This group focuses on managed care organisations, pharmacy benefit managers, and healthcare service providers that operate at the centre of cost containment efforts. These companies are designed to benefit as the healthcare system increasingly emphasises value-based care and operational efficiency in response to new pricing pressures.
Each company was carefully selected for its strategic position within the cost-control ecosystem. From major health insurers managing Medicare Advantage plans to hospital operators reducing pharmaceutical expenses, these firms are positioned to translate systemic healthcare savings into improved margins and profitability.
The U.S. government's successful negotiation of lower prices for key Medicare drugs signals a major shift in pharmaceutical pricing power. This creates a potential investment opportunity in managed care and healthcare service companies poised to benefit from the system's increased focus on cost efficiency.
Erfahren Sie alles über diesen Aktienkorb. Lesen Sie unseren ausführlichen Artikel zu seinen Risiken und seinem Potenzial.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Veröffentlicht am November 26
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
CVS
CVS
Aktueller Kurs
$94.67
Through its integrated health services, including a major pharmacy benefit manager (PBM), the company is positioned to gain from negotiating lower dru...
Through its integrated health services, including a major pharmacy benefit manager (PBM), the company is positioned to gain from negotiating lower drug prices.
Cigna Corp
CI
Aktueller Kurs
$280.78
This global health service company, particularly through its Evernorth health services segment, will likely see improved margins from reduced pharmace...
This global health service company, particularly through its Evernorth health services segment, will likely see improved margins from reduced pharmaceutical expenses.
Join Nemo FREE today and unlock every stock
Es dauert nur 60 Sekunden.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
Wenn Sie in diese Werte investieren:
In 12 Monaten könnte der Wert betragen:
+39.15%
Analysten erwarten im Durchschnitt, dass die Werte dieser Gruppe im nächsten Jahr um 39.15 % zulegen.
12 von 15 Werten dieser Gruppe werden von professionellen Analysten mit „Kaufen“ bewertet.
